 In this video I'm going to talk about a $1.40 penny stock and is it a buy? We'll go through the information in this video. We're going to say I'm not a financial advisor I'm a business teacher, but I'm by no means an expert on the stock market We'll get into this information and this is a penny stock that has got massive institutional investors involved. It's also got commercialization it's moving towards actually commercializing its products and getting some sales and getting some revenues in and that's what the focus is What I see for the penny stock and the main catalyst being for this penny stock will go through this whether it's a buy or not We'll go through the pricing my predictions where I see this going and the strategy for it also towards the end So let's get into the core bits of information if you could smash that like one. It'll be much appreciated It does help us get up into that YouTube search results and algorithms and if you're new to the channel Do consider subscribing we cover many penny stocks and all sorts of growth stocks and Latest information so if that sounds interesting to you then do subscribe. Let's get into the information So what we're going to be talking about today is Zemedica. Okay now just some background information on Zemedica so first of all they have 70 issued and pending patents for Trueformer The beauty of the product is that it allows for adrenaline and thyroid testing on the spot Veterinary clinic so vets don't have to wait for lab results Trueformer is slightly smaller than a desktop printer Yes, sir the the device that they use is is very compact However, one of the issues with Trueformer is the cost price of it So it's eighteen thousand five hundred dollars pair device so What I would say is this is where? Commercialization comes in like the more that they can sell the more they have economies of scale You know the more if they can sell hundreds of these then ultimately they're able to get the cost basis down of these devices So I think that's something to consider for what for towards the future. It's not to say that it's always going to be 18 thousand five hundred pair device I mean if you look towards the future if they're going to expand sales that cost basis could come down However, what's so good about this device is that it has unique advantages so they can actually detect everything from cardiac abnormalities and Dercarin disorders and chronic diseases to tumor markers for starters What more the vast majority of the global three point seven billion pet diagnostic market consists of screening? So again three point six three point seven billion to their three point seven billion dollars in this particular industry there's this got potential here and Again, if the device is unique advantages, and it's something that's that's out there that provides the best quality Advantage for what they're trying to do then it's going to have a unique selling point Okay It has a unique selling point which means that they can charge a premium for this device if they've got some unique selling points to it Okay, it also says even though the company is fully funded until 2023 and expect to turn a profit by then nothing is stopping it from taking it advantage of its stock price Indeed over the last year share count has increased a lot. Yeah, it has increased a lot It's actually being on a downward trend this penny stock, which is why I wanted to cover it I didn't want to cover it when it was like two dollars fifty three dollars as much, right? I want to cover and do a dedicated video when it's a bit cheaper than that So that's what we're doing today, and I do think it's getting towards it buys earn and we'll go into the strategy for that We've also got a lot of institutional investors That buying this penny stock when they own a lot of shares a lot of shares In this penny stock, okay, and this is just sort of fairly recently in 2021 these three Okay, so there's a lot of shares that they currently earn and the green obviously indicates new positions. So they Continually looking at getting an increase in this share share price share current shares on this penny stock and I do believe that That adds some credibility to the penny stock. Okay, because not all institutional investors actually invest in penny stocks. Okay, and They're a bit more selective. So the facts that they're buying this penny stock Tells me that there's there's a lot of potential with it in terms of commercialization and getting its product out there to the to the masses in the pet industry and again It's a billion dollar industry. I've got something. I just want to quickly read out to you And this is on industry analog analysis. This is from the intelligent investor by Benjamin Graham It says here because the general prospects of the enterprise carry major weight in Establishment of market prices is natural for security analysts to divert a great deal of attention to the economic Position of the industry and of the individual company in its industry. So This is important really when you think about the industry itself. It's in the pet industry it's a billion dollar industry and They've actually only sold one product so far now It's only because they've just sort of recently been approved and obviously it's a high-ticket item at $18,000 So what I'd be looking for and the main aspect that I think what people are waiting for What what more institutional investors are waiting for is to see as a medicare actually go out there and sell more of these Devices these true former devices and I think that's where the catalyst lies for it to move back up to its two to three dollar range If they can put up more press releases saying that they're selling more and more of these devices Of increasing their revenue. I see that this is going to impact the share price. That is going to be the main catalyst for this It's not going to necessarily be development of this or or you know Approved patent for this. I believe in this one It's now about commercialization because they've got this product. It's now about commercializing it getting out there getting the sales And that's where I see this one doing. Well, okay, so we're going to look at the economics of this Okay, it's a very expensive device that offers unique selling points I believe that the sales are going to be slightly slower to begin with but as people start to buy these as As the pet industry starts to buy these starts to use the device and you know, they see the benefits of it I think that that is going to Improve sales over time. Okay, so that is really the key, right? This stock is not going to go up unless we see some more sales coming out with this company It's now the time for this company to be commercializing. Okay, it's not about developing. It's now commercializing They need to get the funds in they need to get the revenue rolling in and that's what the the key to the catalyst is Now if you're enjoying this video, do remember to smash the like button Try get this video up into the YouTube search results So people see this penny stock video on zamerica and it is it really does help out and more likes it gets into the YouTube search results and shows up on the side feeds and on the YouTube searches And it really does help us out and also subscribe to the channel as well It really does also help out doing that as well by actually Subscribing it make sure that you know that that we can grow our subscriber count trying to get to 20,000 subscribers So any support you can offer on that and again We cover penny stocks and all sorts of different stocks if that sounds interesting do consider subscribing Let's get into some more information about zamerica So we've also got this remember this in I know this is in February But I just want us to think and it's good to have this kind of historic look at some of the press releases Because it's not just about looking at the latest press release It's looking back and thinking how have they developed over time? What was the roadmap from where they was? you know a Just a couple of months ago here, but where but also you can look even further back to the press releases and think where where was they? You know 8 12 months ago as to where they are have they made a lot of progress all things consider it And I do believe they have made a lot of progress in terms of launching this true former Now what I would say is from now until the next 12 months what I want to see is a lot of press releases in Relation to sales and revenue coming out with that the the sales of these devices of course But remember they announced a closing of 173.5 million bought deal. Okay, and this was art. This was our 91 million common shares a price of $1.90 per share now Of course this is in February You know and we was in the midst of the correction, which is obviously impacted the stock price as well But also the fact that you know that they're not putting out enough press releases on sales So we're seeing that share price there. It's at $1.90 It was and then people you know there was this bought deal So what I would say is that look if you can catch this Towards this low $1 range. I see this as a buy-in opportunity. Okay now Moving into this it's announced its first commercial sale, but what did the medica say about this first commercial sale? So I said my deepest gratitude to many of the people as a medica who dedicated the past two years of their lives to achieve in this critical milestone Okay, we have a unique and viable Valuable diagnostic tool and has delivered it to a veterinary market slightly ahead of our previously announced schedule So that is good. They're actually announcing their first commercial sale in that sense So they've got one sale serve by one first commercial sale But what I would like to see is a lot more sales coming through here of the true former. Okay, that's what I'm waiting for Now the current price you can see it here. It's at $1.40. You can see that it's moved down a lot I mean it's 52 week highs at $2.91 Okay, and that was sort of it You know in the past couple of months or so so it has moved down a lot to $1.47 It's almost half its share price Okay, and it's come down a lot. I mean what I would say is I mean if you look at the six month chart I haven't got this up here on this screen But if you look to the six month, you'll notice that it was hovering around $1 around $1 For quite a while at one point So what I would say is if you can catch this close to the $1 range Okay, $1.40 it could be a potential buy But of course there's more downside to that potentially So if you can get it close to the $1 range like the $1 $1.10 $1.20 I see that as a potential buying opportunity however I'm not too sure with this one in terms of how the share price is going to go, right? So this is an interesting one it depends if they can commercialize they can get more sales through I would say that this could be a more of a medium to long-term play if they are not Commercializing or getting the sales in enough It may just be a kind of get in and get out momentum play where you sort of get it at $1.10 $1.20 and then sell it like $2.50 or something like that and and try and just get a swing trade play on it But again, it's about do you believe in the product if you do? Then you you probably believe that they're going to be able to get a lot more commercial sales through Okay, and I think that the device has got a need for the market in a billion dollar industry market It's just that it is a billion dollar industry market And if that is the case of course they need to take advantage of that and build up their sales That's my only concern if they don't do that this stock could could not do as well because It's now predicated on sales and revenue of the device that they've been developing for all this time Mainly I think that's going to be the key focus here Okay, and that's what I've got for you on this video today If you enjoyed the video then do smash that like button. It really does help support out the channel Okay, so let's get this into the YouTube search results by smashing the like button and also subscribe to the channel If you're new welcome and we'll cover more as a medicare news in the future if you want me to do that Any news that comes out about some medicare I might make videos on it So if that's interesting subscribe But also on any other stocks as well that you would like me to cover but do subscribe for that And I'll see everybody in the next one